Brief: ExpreS2ion: Update On New Clinical Phase Ib Trial For The RH5.1 Blood-Stage Malaria Vaccine

ExpreS2ion Biotech Holding AB

21/07/2021 07:34

July 21 (Reuters) - ExpreS2ion Biotech Holding AB
 EXPRS2.ST :
    * UPDATE ON A NEW CLINICAL PHASE IB TRIAL FOR THE RH5.1
BLOOD-STAGE MALARIA VACCINE
    * PRIMARY AIM OF NEW PHASE IB TRIAL IS TO ASSESS SAFETY AND
IMMUNOGENICITY OF RH5.1/MATRIX-M FORMULATION IN A
MALARIA-ENDEMIC POPULATION FOR FIRST TIME.
    * RH5.1 BLOOD-STAGE MALARIA PROTEIN VACCINE HAS PREVIOUSLY
BEEN
ADMINISTERED TO 67 HEALTHY UK ADULTS, WITH VARIOUS DOSES, AND
WAS FOUND TO BE SAFE AND WELL TOLERATED
    * STUDY IS ESTIMATED TO BE COMPLETED IN H2 2023

Source text for Eikon:  ID:nWkr5bFxVq 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))